ASCO 2020: Researchers underscore efficacy of pembrolizumab plus axitinib in treating advanced renal cell carcinoma - ecancer

Researchers at Fox Chase Cancer Center, along with an international team of investigators, have found that the use of pembrolizumab in combination with axiti

Pembrolizumab plus axitinib in first-line continue to demonstrate superiority compared to sunitinib in patients with clear cell renal cell carcinoma - Onco Americas

PDF) BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

PDF) Emozioni scoperte: A COLLECTION OF AUTOBIOGRAPHICAL TEXTS BY ONCOLOGIC PATIENTS

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial - ScienceDirect

ASCO GU 2021: Outcomes For Patients In the Pembrolizumab+Axitinib Arm With Advanced Renal Cell Carcinoma Who Completed Two Years Of Treatment In The Phase III KEYNOTE-426 Study

ASCO 2021: Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma: Results from 42-Month Follow-up of KEYNOTE-426

PDF) A Systematic Review of Clinical Practice Guidelines for Managing Pulmonary Toxicities Caused by Immune Checkpoint Inhibitors: Quality of Treatment Recommendations and Differences in Management Strategies Between Guidelines

PDF) A Systematic Review of Clinical Practice Guidelines for Managing Pulmonary Toxicities Caused by Immune Checkpoint Inhibitors: Quality of Treatment Recommendations and Differences in Management Strategies Between Guidelines

ASCO 2021: Pembrolizumab (Pembro) plus Axitinib (Axi) Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Results from 42-Month Follow-up of KEYNOTE-426